<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859885</url>
  </required_header>
  <id_info>
    <org_study_id>117/08</org_study_id>
    <nct_id>NCT00859885</nct_id>
  </id_info>
  <brief_title>International PFO Consortium</brief_title>
  <official_title>Secondary Stroke Prevention In Patients With Patent Foramen Ovale: International PFO Consortium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of Aarau, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alfried-Krupp Krankenhaus of Essen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Worms</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>East Medical Center Tyler, Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ammerland Klinik GmbH, Westerstede, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of patent foramen ovale (PFO) is about 25% in the general population and
      approximately 40% in patients who have ischemic stroke of unknown cause (cryptogenic stroke).
      Given the large number of asymptomatic patients, no primary prevention is currently
      recommended. On the contrary, secondary prevention is very important. Prospective studies
      have shown that antithrombotic treatment (ATT) with aspirin or warfarin appears to negate the
      risk of recurrent stroke associated with a PFO. Patients with spontaneous or large
      right-to-left shunts (RLS), those with a coinciding atrial septal aneurysm (ASA) or multiple
      ischemic events prior to the PFO diagnosis may still be at increased risk of stroke
      recurrence despite ATT. Percutaneous device closure (PDC) is a challenging alternative to
      ATT. Several studies reported 0% to 3.4% annual recurrence rates of stroke or TIA in patients
      treated by PDC. To date, there is no data from randomized controlled trials (RCT) comparing
      the risk of stroke recurrence after PDC with that under ATT only. The results from ongoing
      RCTs are not to be awaited in the near future, mainly due to low enrolment and event rates.
      Alternative data-gathering strategies such as multicenter registries are needed to overcome
      the low recruitment rates. The aim of the present study is to compare the risk of recurrent
      stroke and TIA in patients with PFO and otherwise unexplained stroke who undergo PDC or
      receive ATT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      The prevalence of patent foramen ovale (PFO) is about 25% in the general population and
      approximately 40% in patients who have ischemic stroke of unknown cause (cryptogenic stroke).
      Given the large number of asymptomatic patients, no primary prevention is currently
      recommended. On the contrary, secondary prevention is very important. Prospective studies
      have shown that antithrombotic treatment (ATT) with aspirin or warfarin appears to negate the
      risk of recurrent stroke associated with a PFO. Patients with spontaneous or large
      right-to-left shunts (RLS), those with a coinciding atrial septal aneurysm (ASA) or multiple
      ischemic events prior to the PFO diagnosis may still be at increased risk of stroke
      recurrence despite ATT. Percutaneous device closure (PDC) is a challenging alternative to
      ATT. Several studies reported 0% to 3.4% annual recurrence rates of stroke or TIA in patients
      treated by PDC. To date, there is no data from randomized controlled trials (RCT) comparing
      the risk of stroke recurrence after PDC with that under ATT only. The results from ongoing
      RCTs are not to be awaited in the near future, mainly due to low enrolment and event rates.
      Even if RCTs are completed successfully, statistical differences may remain undetected with
      the planned sample sizes. Alternative data-gathering strategies such as multicenter
      registries are needed to overcome the low recruitment rates.

      Objective

      1) To compare the risk of recurrent stroke and TIA in patients aged ≤ 55 years with PFO and
      otherwise unexplained stroke who undergo PDC or receive ATT only; 2) To assess the
      etiological role of PFO for stroke/TIA in patients aged &gt; 55 years; 3) To assess the risk of
      recurrent stroke/TIA in &quot;high-risk&quot; PFO patients (i.e. those with spontaneous (at rest) or
      large RLS, coinciding ASA, or multiple previous cerebrovascular events).

      Methods

      Multicenter prospective non-randomized study with scheduled 3-years follow-up of patients
      with PFO and ischemic stroke or TIA. Participating centers: Swiss University Hospitals of
      Basel, Bern, Geneva, Lausanne and Zurich, the Cantonal Hospital of Aarau, the Triemli
      Hospital, the Alfried-Krupp Krankenhaus of Essen, the University Hospital of Essen, the
      Klinikum Worms gGmbH, Tufts Medical Center, Baystate Medical Center, the East Medical Center
      Tyler, and the University Hospital of Leuven.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2008</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients free of any stroke (including fatal stroke) or TIA</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>influence of gender, age, spontaneous or large shunt, coincidence of an atrial septum aneurysma</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>influence of competitive causes of stroke</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of residual shunt, (in)correct device position, need for implantation of second device and periprocedural complications</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients who receive antithrombotic treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients who undergo percutaneous device closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombotic treatment</intervention_name>
    <description>antiplatelets, anticoagulants</description>
    <arm_group_label>1</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>percutaneous device closure of PFO</intervention_name>
    <description>umbrella device for PFO closure</description>
    <arm_group_label>2</arm_group_label>
    <other_name>clopidogrel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic stroke or transient ischemic attacks, in whom a patent foramen ovale
        has been diagnosed by means of a transesophageal echocardiography
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Diagnosis of PFO established by transesophageal echocardiography (TEE)

          -  Ischemic stroke or transient ischemic attack within the previous 6 months

        Exclusion Criteria

          -  Non-vascular origin of the neurological symptoms after brain imaging (CT scan or MRI)

          -  Comorbid condition that would interfere with the study

          -  Pregnancy

          -  History of intracranial bleeding, confirmed arterio-venous malformation, aneurysm or
             uncontrolled coagulopathy

          -  Contraindications for TEE, echocardiographic or iodine contrast media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krassen Nedeltchev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Aarau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Luise Mono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Neurology, Bern University Hospital, Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcel Arnold, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Bern, Inselspital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krassen Nedeltchev, MD</last_name>
    <phone>+41 62 838 66 75</phone>
    <email>Krassen.Nedeltchev@ksa.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Luise Mono, MD</last_name>
    <phone>+41316320743</phone>
    <email>marie-luise.mono@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>East Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Hemelsoet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leuven University Hospital</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Essen University Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ammerland Klinik GmbH</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Müller-Eichelberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Worms gGmbH</name>
      <address>
        <city>Worms</city>
        <zip>67550</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova, Department of Neurology, ASMN IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17707</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquín Serena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Bern University Hospital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Luise Mono</last_name>
      <phone>+41316320743</phone>
      <email>marie-luise.mono@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Marie-Luise Mono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Meier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Arnold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zürich Triemli Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Zürich University Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pfoconsortium.org</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Krassen Nedeltchev</name_title>
    <organization>University of Bern and Triemli Hospital Zurich</organization>
  </responsible_party>
  <keyword>patent foramen ovale</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>transient ischemic attack</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>medical treatment</keyword>
  <keyword>percutaneous device closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

